Increasing compliance with Active surveillance: A randomised trial evaluating the role of Finasteride

The study is a randomised controlled CTIMP in men with newly diagnosed low/intermediate risk localised prostate cancer. We will randomise 550 patients to Active Surveillance with or without once daily finasteride. Patients will receive finasteride for 2-years and will be followed up for an average of 4-years.

Active surveillance will include PSA, re-biopsy and MRI as per usual NHS care. The primary outcome is adherence with Active Surveillance in both arms.